Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8156607 | 0.86 | GRM2 (0.59) | GRM2 | |
| SCHEMBL1827635 | 0.75 | GRM2 (0.75) | GRM2 | |
| SCHEMBL1828242 | 0.67 | GRM2 (0.57) | GRM2 | |
| SCHEMBL1828011 | 0.67 | LMNA (0.57) | GRM2 | |
| SCHEMBL10324147 | 0.66 | GRM2 (1.00) | GRM2 | |
| SCHEMBL1829294 | 0.66 | GRM2 (0.56) | GRM2 | |
| SCHEMBL1827879 | 0.66 | GRM2 (0.59) | GRM2 | |
| SCHEMBL171758 | 0.66 | GRM2 (0.62) | GRM2 | |
| SCHEMBL741461 | 0.65 | GRM2 (1.00) | GRM2 | |
| SCHEMBL171300 | 0.65 | GRM2 (0.81) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| EP-2134708-B1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2134708-B1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil Janssen Pharmaceuticals Inc. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil Janssen Pharmaceuticals Inc. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil Janssen Pharmaceuticals Inc. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2134708-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107481-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRIK2 | GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.